A. Tammaro, G. Adebanjo, E. Gelormini, Maria Elisabetta Greco, F. Parisella, Camilla Chello, G. De Marco, Fabiola Luzi
{"title":"Homemade lip injection for cosmetic purpose: A case report","authors":"A. Tammaro, G. Adebanjo, E. Gelormini, Maria Elisabetta Greco, F. Parisella, Camilla Chello, G. De Marco, Fabiola Luzi","doi":"10.25259/ijsa_42_2023","DOIUrl":"https://doi.org/10.25259/ijsa_42_2023","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":" 48","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140213700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cutaneous leukocytoclastic vasculitis (LCV) that primarily affects the skin, can be idiopathic or linked to infections, autoimmune diseases, neoplasms, and medications. An immune complex-mediated vasculitis of the dermal capillaries and venules is the histological hallmark of LCV, a small vessel vasculitis. This case report describes a 36-year previously healthy man who was presented to the outpatient department (OPD) with complaints of edema and development of numerous reddish-purple patches (caused by petechiae) after intake of cough syrup containing ambroxol. Ambroxol affects human monocytic cells THP-1, and prevents the generation of platelet-derived growth factor (PDGF)-AB that is produced by lipopolysaccharide (LPS) by inhibiting the expression of PDGF-A messenger Ribonucleic acid (RNA). An extracellular signal-regulated kinase (ERK) on p44/42 is activated by LPS, and ambroxol reduces this activation. In addition, 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD 98059), a Mitogen-Activated Protein Kinase Inhibitors (MEK), MEK-1-specific inhibitor, prevents p44/42 ERK activation and PDGF synthesis brought on by LPS. Megakaryocytes, erythrocytes, leukocytes, and their progenitors are stimulated to multiply by PDGF to the numerous endogenous growth factors that mesenchymal stem and stromal cells secrete. Ambroxol reduces the number of megakaryocytic progenitors and boosts apoptosis by inhibiting the production of PDGF and related signaling pathways. It is strongly advised that patients must be made more aware of the risks associated with using such over-the-counter medications.
{"title":"Ambroxol-induced leukocytoclastic vasculitis: A case report and literature review","authors":"Ankit Bhardwaj, Manik S. Ghadlinge","doi":"10.25259/ijsa_37_2023","DOIUrl":"https://doi.org/10.25259/ijsa_37_2023","url":null,"abstract":"Cutaneous leukocytoclastic vasculitis (LCV) that primarily affects the skin, can be idiopathic or linked to infections, autoimmune diseases, neoplasms, and medications. An immune complex-mediated vasculitis of the dermal capillaries and venules is the histological hallmark of LCV, a small vessel vasculitis. This case report describes a 36-year previously healthy man who was presented to the outpatient department (OPD) with complaints of edema and development of numerous reddish-purple patches (caused by petechiae) after intake of cough syrup containing ambroxol. Ambroxol affects human monocytic cells THP-1, and prevents the generation of platelet-derived growth factor (PDGF)-AB that is produced by lipopolysaccharide (LPS) by inhibiting the expression of PDGF-A messenger Ribonucleic acid (RNA). An extracellular signal-regulated kinase (ERK) on p44/42 is activated by LPS, and ambroxol reduces this activation. In addition, 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD 98059), a Mitogen-Activated Protein Kinase Inhibitors (MEK), MEK-1-specific inhibitor, prevents p44/42 ERK activation and PDGF synthesis brought on by LPS. Megakaryocytes, erythrocytes, leukocytes, and their progenitors are stimulated to multiply by PDGF to the numerous endogenous growth factors that mesenchymal stem and stromal cells secrete. Ambroxol reduces the number of megakaryocytic progenitors and boosts apoptosis by inhibiting the production of PDGF and related signaling pathways. It is strongly advised that patients must be made more aware of the risks associated with using such over-the-counter medications.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140449577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abhishek De, Disha Chakraborty, B. N. Grisilda, Sirshendu Chaudhuri, K. Godse, Sandipan Dhar
Managing mild-to-moderate atopic dermatitis (AD) often necessitates topical therapies, and one such recently introduced option is crisaborole ointment. This study sets out to assess the efficacy and safety of crisaborole ointment in pediatric cases of AD over four weeks. Nineteen children between 2 and 16 years old with mild-to-moderate AD were enrolled and treated with crisaborole ointment twice daily in affected areas for 30 days. The primary objective was to appraise the shift in the investigator’s static global assessment (ISGA) scores (0–4) every week for the four-week follow-up. The severity of pruritus score (SPS) was another secondary objective. Furthermore, individual indicators of clinical signs that included erythema, exudation, excoriation, induration/papulation, and lichenification, were examined with subjective scores (0–3). Children’s dermatology quality of life index (CDLQI) was employed to study the quality of life. Following four weeks of crisaborole ointment treatment, the average ISGA score declined from 2.58 ± 0.61 to 0.95 ± 0.78, signifying a substantial reduction in AD severity (P < 0.001). The SPS score also decreased from a mean of 2.32 ± 0.478 to 0.84 ± 0.60 (P < 0.001), underscoring a significant reduction in itching. Moreover, individual markers for clinical signs of AD, including erythema, exudation, excoriation, induration/papulation, and lichenification, all exhibited statistically significant improvement. Crisaborole ointment was well tolerated. Only 6 of the 19 patients reported a localized burning sensation, which was manageable. No patient needed to be withdrawn during the study period. The CDLQI showed a substantial drop in scores, decreasing from an average of 13.79 ± 3.57 at the commencement to 6.74 ± 1.97 (P < 0.001). Furthermore, 14 out of 19 patients met the study’s primary goal, achieving at least a 2-point reduction in ISGA along with the attainment of clear or nearly clear skin (ISGA 0–1). Our study found crisaborole ointment significantly improved pediatric AD symptoms and was well-tolerated. The only adverse event was localized burning in a few patients. Further, research is needed for validation.
{"title":"Efficacy and safety of crisaborole ointment in pediatric atopic dermatitis: A 4-week open-label study","authors":"Abhishek De, Disha Chakraborty, B. N. Grisilda, Sirshendu Chaudhuri, K. Godse, Sandipan Dhar","doi":"10.25259/ijsa_45_2023","DOIUrl":"https://doi.org/10.25259/ijsa_45_2023","url":null,"abstract":"\u0000\u0000Managing mild-to-moderate atopic dermatitis (AD) often necessitates topical therapies, and one such recently introduced option is crisaborole ointment. This study sets out to assess the efficacy and safety of crisaborole ointment in pediatric cases of AD over four weeks.\u0000\u0000\u0000\u0000Nineteen children between 2 and 16 years old with mild-to-moderate AD were enrolled and treated with crisaborole ointment twice daily in affected areas for 30 days. The primary objective was to appraise the shift in the investigator’s static global assessment (ISGA) scores (0–4) every week for the four-week follow-up. The severity of pruritus score (SPS) was another secondary objective. Furthermore, individual indicators of clinical signs that included erythema, exudation, excoriation, induration/papulation, and lichenification, were examined with subjective scores (0–3). Children’s dermatology quality of life index (CDLQI) was employed to study the quality of life.\u0000\u0000\u0000\u0000Following four weeks of crisaborole ointment treatment, the average ISGA score declined from 2.58 ± 0.61 to 0.95 ± 0.78, signifying a substantial reduction in AD severity (P < 0.001). The SPS score also decreased from a mean of 2.32 ± 0.478 to 0.84 ± 0.60 (P < 0.001), underscoring a significant reduction in itching. Moreover, individual markers for clinical signs of AD, including erythema, exudation, excoriation, induration/papulation, and lichenification, all exhibited statistically significant improvement. Crisaborole ointment was well tolerated. Only 6 of the 19 patients reported a localized burning sensation, which was manageable. No patient needed to be withdrawn during the study period. The CDLQI showed a substantial drop in scores, decreasing from an average of 13.79 ± 3.57 at the commencement to 6.74 ± 1.97 (P < 0.001). Furthermore, 14 out of 19 patients met the study’s primary goal, achieving at least a 2-point reduction in ISGA along with the attainment of clear or nearly clear skin (ISGA 0–1).\u0000\u0000\u0000\u0000Our study found crisaborole ointment significantly improved pediatric AD symptoms and was well-tolerated. The only adverse event was localized burning in a few patients. Further, research is needed for validation.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"118 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139843634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abhishek De, Disha Chakraborty, B. N. Grisilda, Sirshendu Chaudhuri, K. Godse, Sandipan Dhar
Managing mild-to-moderate atopic dermatitis (AD) often necessitates topical therapies, and one such recently introduced option is crisaborole ointment. This study sets out to assess the efficacy and safety of crisaborole ointment in pediatric cases of AD over four weeks. Nineteen children between 2 and 16 years old with mild-to-moderate AD were enrolled and treated with crisaborole ointment twice daily in affected areas for 30 days. The primary objective was to appraise the shift in the investigator’s static global assessment (ISGA) scores (0–4) every week for the four-week follow-up. The severity of pruritus score (SPS) was another secondary objective. Furthermore, individual indicators of clinical signs that included erythema, exudation, excoriation, induration/papulation, and lichenification, were examined with subjective scores (0–3). Children’s dermatology quality of life index (CDLQI) was employed to study the quality of life. Following four weeks of crisaborole ointment treatment, the average ISGA score declined from 2.58 ± 0.61 to 0.95 ± 0.78, signifying a substantial reduction in AD severity (P < 0.001). The SPS score also decreased from a mean of 2.32 ± 0.478 to 0.84 ± 0.60 (P < 0.001), underscoring a significant reduction in itching. Moreover, individual markers for clinical signs of AD, including erythema, exudation, excoriation, induration/papulation, and lichenification, all exhibited statistically significant improvement. Crisaborole ointment was well tolerated. Only 6 of the 19 patients reported a localized burning sensation, which was manageable. No patient needed to be withdrawn during the study period. The CDLQI showed a substantial drop in scores, decreasing from an average of 13.79 ± 3.57 at the commencement to 6.74 ± 1.97 (P < 0.001). Furthermore, 14 out of 19 patients met the study’s primary goal, achieving at least a 2-point reduction in ISGA along with the attainment of clear or nearly clear skin (ISGA 0–1). Our study found crisaborole ointment significantly improved pediatric AD symptoms and was well-tolerated. The only adverse event was localized burning in a few patients. Further, research is needed for validation.
{"title":"Efficacy and safety of crisaborole ointment in pediatric atopic dermatitis: A 4-week open-label study","authors":"Abhishek De, Disha Chakraborty, B. N. Grisilda, Sirshendu Chaudhuri, K. Godse, Sandipan Dhar","doi":"10.25259/ijsa_45_2023","DOIUrl":"https://doi.org/10.25259/ijsa_45_2023","url":null,"abstract":"\u0000\u0000Managing mild-to-moderate atopic dermatitis (AD) often necessitates topical therapies, and one such recently introduced option is crisaborole ointment. This study sets out to assess the efficacy and safety of crisaborole ointment in pediatric cases of AD over four weeks.\u0000\u0000\u0000\u0000Nineteen children between 2 and 16 years old with mild-to-moderate AD were enrolled and treated with crisaborole ointment twice daily in affected areas for 30 days. The primary objective was to appraise the shift in the investigator’s static global assessment (ISGA) scores (0–4) every week for the four-week follow-up. The severity of pruritus score (SPS) was another secondary objective. Furthermore, individual indicators of clinical signs that included erythema, exudation, excoriation, induration/papulation, and lichenification, were examined with subjective scores (0–3). Children’s dermatology quality of life index (CDLQI) was employed to study the quality of life.\u0000\u0000\u0000\u0000Following four weeks of crisaborole ointment treatment, the average ISGA score declined from 2.58 ± 0.61 to 0.95 ± 0.78, signifying a substantial reduction in AD severity (P < 0.001). The SPS score also decreased from a mean of 2.32 ± 0.478 to 0.84 ± 0.60 (P < 0.001), underscoring a significant reduction in itching. Moreover, individual markers for clinical signs of AD, including erythema, exudation, excoriation, induration/papulation, and lichenification, all exhibited statistically significant improvement. Crisaborole ointment was well tolerated. Only 6 of the 19 patients reported a localized burning sensation, which was manageable. No patient needed to be withdrawn during the study period. The CDLQI showed a substantial drop in scores, decreasing from an average of 13.79 ± 3.57 at the commencement to 6.74 ± 1.97 (P < 0.001). Furthermore, 14 out of 19 patients met the study’s primary goal, achieving at least a 2-point reduction in ISGA along with the attainment of clear or nearly clear skin (ISGA 0–1).\u0000\u0000\u0000\u0000Our study found crisaborole ointment significantly improved pediatric AD symptoms and was well-tolerated. The only adverse event was localized burning in a few patients. Further, research is needed for validation.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"13 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139783568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arpit Jain, Varun Goyal, S. Soni, S. Narayan, P. Redhu, S. Shivarudraiah, V. Talwar
Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, is a common side effect of pazopanib therapy. However, it usually develops gradually over a span of few months. This article will provide a comprehensive analysis of hair depigmentation in patients treated with pazopanib, focusing on the various aspects of this phenomenon, including its onset, possible causes, and potential implications for therapy success. Multitargeted tyrosine kinase inhibitors (MKIs) including pazopanib are recommended for various malignancies. Hair color changes are known side effects of MKIs. The exact mechanisms behind hair depigmentation due to pazopanib therapy are not yet fully understood. However, researchers believe that several factors may contribute to this phenomenon. We presented a case of a patient with relapse Ewings sarcoma who experienced rapid hair depigmentation during pazopanib therapy.
{"title":"Hair depigmentation in a patient treated with pazopanib: A case report and a comprehensive analysis","authors":"Arpit Jain, Varun Goyal, S. Soni, S. Narayan, P. Redhu, S. Shivarudraiah, V. Talwar","doi":"10.25259/ijsa_52_2023","DOIUrl":"https://doi.org/10.25259/ijsa_52_2023","url":null,"abstract":"Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, is a common side effect of pazopanib therapy. However, it usually develops gradually over a span of few months. This article will provide a comprehensive analysis of hair depigmentation in patients treated with pazopanib, focusing on the various aspects of this phenomenon, including its onset, possible causes, and potential implications for therapy success. Multitargeted tyrosine kinase inhibitors (MKIs) including pazopanib are recommended for various malignancies. Hair color changes are known side effects of MKIs. The exact mechanisms behind hair depigmentation due to pazopanib therapy are not yet fully understood. However, researchers believe that several factors may contribute to this phenomenon. We presented a case of a patient with relapse Ewings sarcoma who experienced rapid hair depigmentation during pazopanib therapy.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"17 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139865341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arpit Jain, Varun Goyal, S. Soni, S. Narayan, P. Redhu, S. Shivarudraiah, V. Talwar
Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, is a common side effect of pazopanib therapy. However, it usually develops gradually over a span of few months. This article will provide a comprehensive analysis of hair depigmentation in patients treated with pazopanib, focusing on the various aspects of this phenomenon, including its onset, possible causes, and potential implications for therapy success. Multitargeted tyrosine kinase inhibitors (MKIs) including pazopanib are recommended for various malignancies. Hair color changes are known side effects of MKIs. The exact mechanisms behind hair depigmentation due to pazopanib therapy are not yet fully understood. However, researchers believe that several factors may contribute to this phenomenon. We presented a case of a patient with relapse Ewings sarcoma who experienced rapid hair depigmentation during pazopanib therapy.
{"title":"Hair depigmentation in a patient treated with pazopanib: A case report and a comprehensive analysis","authors":"Arpit Jain, Varun Goyal, S. Soni, S. Narayan, P. Redhu, S. Shivarudraiah, V. Talwar","doi":"10.25259/ijsa_52_2023","DOIUrl":"https://doi.org/10.25259/ijsa_52_2023","url":null,"abstract":"Pazopanib is a multitargeted tyrosine kinase inhibitor used for the treatment of various solid tumor malignancies. Hair color change, particularly hair depigmentation, is a common side effect of pazopanib therapy. However, it usually develops gradually over a span of few months. This article will provide a comprehensive analysis of hair depigmentation in patients treated with pazopanib, focusing on the various aspects of this phenomenon, including its onset, possible causes, and potential implications for therapy success. Multitargeted tyrosine kinase inhibitors (MKIs) including pazopanib are recommended for various malignancies. Hair color changes are known side effects of MKIs. The exact mechanisms behind hair depigmentation due to pazopanib therapy are not yet fully understood. However, researchers believe that several factors may contribute to this phenomenon. We presented a case of a patient with relapse Ewings sarcoma who experienced rapid hair depigmentation during pazopanib therapy.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"18 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139805556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic urticaria (CU) is an unexplained problem that needs to be addressed, and since patients also experience the morbidity associated with irritable itch, they must take a significant quantum of antihistamines. Autoantibodies in the blood cause recurrent flare-ups in autoreactive urticaria when the symptoms are more noticeable. As a result, the need for an adjuvant drug to lessen the weight of pills is felt. The aim of this study was to find out the effectiveness of oral methotrexate (MTX) pulse with antihistamines in chronic refractory urticaria. This was the present longitudinal intervention. The study lasted six months and was carried out at the Department of Dermatology in a hospital with tertiary care status. Fifty patients of chronic spontaneous urticaria have been selected by simple random sampling. All subjects have been given Oral Methotrexate, 15 mg once weekly along with folic acid. Besides, MTX all cases have been given oral desloratadine 5 mg twice daily. Most patients have seen a significant decline in urticaria activity score 7 (UAS7) and dermatological life quality index. The baseline mean UAS7 reduced significantly from 30.16 ± 8.65 to 1.24 ± 2.24 with a statistically significant P < 0.01. No serious side effects were seen except mildly raised liver transaminases in seven patients. When standard second-generation antihistamines are insufficient at treating chronic uncontrolled urticaria, MTX is a very safe, well-tolerated, and economical treatment option.
{"title":"Study of effectiveness of methotrexate oral pulse in refractory chronic urticaria","authors":"Arun Kumar Yadav","doi":"10.25259/ijsa_28_2023","DOIUrl":"https://doi.org/10.25259/ijsa_28_2023","url":null,"abstract":"\u0000\u0000Chronic urticaria (CU) is an unexplained problem that needs to be addressed, and since patients also experience the morbidity associated with irritable itch, they must take a significant quantum of antihistamines. Autoantibodies in the blood cause recurrent flare-ups in autoreactive urticaria when the symptoms are more noticeable. As a result, the need for an adjuvant drug to lessen the weight of pills is felt. The aim of this study was to find out the effectiveness of oral methotrexate (MTX) pulse with antihistamines in chronic refractory urticaria.\u0000\u0000\u0000\u0000This was the present longitudinal intervention. The study lasted six months and was carried out at the Department of Dermatology in a hospital with tertiary care status. Fifty patients of chronic spontaneous urticaria have been selected by simple random sampling. All subjects have been given Oral Methotrexate, 15 mg once weekly along with folic acid. Besides, MTX all cases have been given oral desloratadine 5 mg twice daily.\u0000\u0000\u0000\u0000Most patients have seen a significant decline in urticaria activity score 7 (UAS7) and dermatological life quality index. The baseline mean UAS7 reduced significantly from 30.16 ± 8.65 to 1.24 ± 2.24 with a statistically significant P < 0.01. No serious side effects were seen except mildly raised liver transaminases in seven patients.\u0000\u0000\u0000\u0000When standard second-generation antihistamines are insufficient at treating chronic uncontrolled urticaria, MTX is a very safe, well-tolerated, and economical treatment option.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"138 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139828190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic urticaria (CU) is an unexplained problem that needs to be addressed, and since patients also experience the morbidity associated with irritable itch, they must take a significant quantum of antihistamines. Autoantibodies in the blood cause recurrent flare-ups in autoreactive urticaria when the symptoms are more noticeable. As a result, the need for an adjuvant drug to lessen the weight of pills is felt. The aim of this study was to find out the effectiveness of oral methotrexate (MTX) pulse with antihistamines in chronic refractory urticaria. This was the present longitudinal intervention. The study lasted six months and was carried out at the Department of Dermatology in a hospital with tertiary care status. Fifty patients of chronic spontaneous urticaria have been selected by simple random sampling. All subjects have been given Oral Methotrexate, 15 mg once weekly along with folic acid. Besides, MTX all cases have been given oral desloratadine 5 mg twice daily. Most patients have seen a significant decline in urticaria activity score 7 (UAS7) and dermatological life quality index. The baseline mean UAS7 reduced significantly from 30.16 ± 8.65 to 1.24 ± 2.24 with a statistically significant P < 0.01. No serious side effects were seen except mildly raised liver transaminases in seven patients. When standard second-generation antihistamines are insufficient at treating chronic uncontrolled urticaria, MTX is a very safe, well-tolerated, and economical treatment option.
{"title":"Study of effectiveness of methotrexate oral pulse in refractory chronic urticaria","authors":"Arun Kumar Yadav","doi":"10.25259/ijsa_28_2023","DOIUrl":"https://doi.org/10.25259/ijsa_28_2023","url":null,"abstract":"\u0000\u0000Chronic urticaria (CU) is an unexplained problem that needs to be addressed, and since patients also experience the morbidity associated with irritable itch, they must take a significant quantum of antihistamines. Autoantibodies in the blood cause recurrent flare-ups in autoreactive urticaria when the symptoms are more noticeable. As a result, the need for an adjuvant drug to lessen the weight of pills is felt. The aim of this study was to find out the effectiveness of oral methotrexate (MTX) pulse with antihistamines in chronic refractory urticaria.\u0000\u0000\u0000\u0000This was the present longitudinal intervention. The study lasted six months and was carried out at the Department of Dermatology in a hospital with tertiary care status. Fifty patients of chronic spontaneous urticaria have been selected by simple random sampling. All subjects have been given Oral Methotrexate, 15 mg once weekly along with folic acid. Besides, MTX all cases have been given oral desloratadine 5 mg twice daily.\u0000\u0000\u0000\u0000Most patients have seen a significant decline in urticaria activity score 7 (UAS7) and dermatological life quality index. The baseline mean UAS7 reduced significantly from 30.16 ± 8.65 to 1.24 ± 2.24 with a statistically significant P < 0.01. No serious side effects were seen except mildly raised liver transaminases in seven patients.\u0000\u0000\u0000\u0000When standard second-generation antihistamines are insufficient at treating chronic uncontrolled urticaria, MTX is a very safe, well-tolerated, and economical treatment option.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"103 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139887900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Bhat, Mohd Shurjeel Ul Islam, Sheikh Javeed Sultan
Pigmented contact dermatitis (PCD) is a disorder brought on by repeated exposure to low-intensity allergens, usually presenting as blotchy or reticulate slate-gray pigmentation affecting Fitzpatrick skin type IV-VI. The pathogenesis remains unclear; however, type IV hypersensitivity reactions due to allergic sensitization, genetics, ultraviolet exposure, and autoimmunity are to blame. Clinical examination, dermoscopy, patch/photo patch testing, histopathology, and recently, a novel reflectance confocal microscopy and multimodality skin imaging system aid in the diagnosis. Several contact allergens have been linked to PCD, but from an Indian perspective, Kumkum and Paraphenylenediamine are the incriminating agents. Patch testing plays an immense role whenever PCD is diagnosed, primarily due to contact allergens. Devastating psychological impacts can result from PCD-related deformity on social acceptance, mental health, and self-esteem. Avoiding allergens, wearing broad-spectrum sunscreen, and engaging in sun-protective behavior are general measures for treating the condition.
{"title":"Pigmented contact dermatitis: An updated review","authors":"Y. Bhat, Mohd Shurjeel Ul Islam, Sheikh Javeed Sultan","doi":"10.25259/ijsa_44_2023","DOIUrl":"https://doi.org/10.25259/ijsa_44_2023","url":null,"abstract":"Pigmented contact dermatitis (PCD) is a disorder brought on by repeated exposure to low-intensity allergens, usually presenting as blotchy or reticulate slate-gray pigmentation affecting Fitzpatrick skin type IV-VI. The pathogenesis remains unclear; however, type IV hypersensitivity reactions due to allergic sensitization, genetics, ultraviolet exposure, and autoimmunity are to blame. Clinical examination, dermoscopy, patch/photo patch testing, histopathology, and recently, a novel reflectance confocal microscopy and multimodality skin imaging system aid in the diagnosis. Several contact allergens have been linked to PCD, but from an Indian perspective, Kumkum and Paraphenylenediamine are the incriminating agents. Patch testing plays an immense role whenever PCD is diagnosed, primarily due to contact allergens. Devastating psychological impacts can result from PCD-related deformity on social acceptance, mental health, and self-esteem. Avoiding allergens, wearing broad-spectrum sunscreen, and engaging in sun-protective behavior are general measures for treating the condition.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"19 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139889423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Bhat, Mohd Shurjeel Ul Islam, Sheikh Javeed Sultan
Pigmented contact dermatitis (PCD) is a disorder brought on by repeated exposure to low-intensity allergens, usually presenting as blotchy or reticulate slate-gray pigmentation affecting Fitzpatrick skin type IV-VI. The pathogenesis remains unclear; however, type IV hypersensitivity reactions due to allergic sensitization, genetics, ultraviolet exposure, and autoimmunity are to blame. Clinical examination, dermoscopy, patch/photo patch testing, histopathology, and recently, a novel reflectance confocal microscopy and multimodality skin imaging system aid in the diagnosis. Several contact allergens have been linked to PCD, but from an Indian perspective, Kumkum and Paraphenylenediamine are the incriminating agents. Patch testing plays an immense role whenever PCD is diagnosed, primarily due to contact allergens. Devastating psychological impacts can result from PCD-related deformity on social acceptance, mental health, and self-esteem. Avoiding allergens, wearing broad-spectrum sunscreen, and engaging in sun-protective behavior are general measures for treating the condition.
{"title":"Pigmented contact dermatitis: An updated review","authors":"Y. Bhat, Mohd Shurjeel Ul Islam, Sheikh Javeed Sultan","doi":"10.25259/ijsa_44_2023","DOIUrl":"https://doi.org/10.25259/ijsa_44_2023","url":null,"abstract":"Pigmented contact dermatitis (PCD) is a disorder brought on by repeated exposure to low-intensity allergens, usually presenting as blotchy or reticulate slate-gray pigmentation affecting Fitzpatrick skin type IV-VI. The pathogenesis remains unclear; however, type IV hypersensitivity reactions due to allergic sensitization, genetics, ultraviolet exposure, and autoimmunity are to blame. Clinical examination, dermoscopy, patch/photo patch testing, histopathology, and recently, a novel reflectance confocal microscopy and multimodality skin imaging system aid in the diagnosis. Several contact allergens have been linked to PCD, but from an Indian perspective, Kumkum and Paraphenylenediamine are the incriminating agents. Patch testing plays an immense role whenever PCD is diagnosed, primarily due to contact allergens. Devastating psychological impacts can result from PCD-related deformity on social acceptance, mental health, and self-esteem. Avoiding allergens, wearing broad-spectrum sunscreen, and engaging in sun-protective behavior are general measures for treating the condition.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"54 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：